Evogene Ltd. (NASDAQ:EVGN) Short Interest Up 414.3% in August

28 Aug 2026, 01:40 by Danessa Lincoln · The Markets Daily

Evogene Ltd. (NASDAQ:EVGN – Get Free Report) was the recipient of a large increase in short interest during the month of August. As of August 14th, there was short interest totaling 232,078 shares, an increase of 414.3% from the July 30th total of 45,127 shares. Based on an average daily trading volume, of 994,693 shares, the short-interest ratio is presently 0.2 days. Approximately 2.9% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Evogene in a research report on Wednesday, July 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Read Our Latest Stock Report on Evogene

Evogene Stock Performance

EVGN stock traded down $0.01 during trading on Thursday, reaching $0.54. The company had a trading volume of 59,476 shares, compared to its average volume of 663,279. The company has a market cap of $4.69 million, a price-to-earnings ratio of -0.59 and a beta of 1.40. Evogene has a twelve month low of $0.37 and a twelve month high of $1.50. The firm has a 50-day simple moving average of $0.53 and a 200-day simple moving average of $0.69.

Insider Activity at Evogene

In other news, Director Leon Recanati acquired 460,000 shares of Evogene stock in a transaction that occurred on Tuesday, August 11th. The stock was purchased at an average price of $0.64 per share, for a total transaction of $294,400.00. Following the purchase, the director directly owned 1,343,886 shares in the company, valued at $860,087.04. The trade was a 52.04% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. 7.40% of the stock is currently owned by company insiders.

Institutional Trading of Evogene

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Citadel Advisors LLC grew its stake in Evogene by 169.4% during the 3rd quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 36,206 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of Evogene by 58.0% during the first quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 12,387 shares during the period. Finally, XTX Topco Ltd purchased a new stake in Evogene in the fourth quarter valued at approximately $25,000. Institutional investors and hedge funds own 10.40% of the company’s stock.

About Evogene

(Get Free Report)

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.